{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:48:34Z","timestamp":1788364114446,"version":"build-2803163510"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Botulinum toxin A (BoNT-A) has been widely used in several urological functional disorders including neurogenic detrusor overactivity (NDO), overactive bladder (OAB), lower urinary tract dysfunction, and interstitial cystitis\/bladder pain syndrome (IC\/BPS). Chronic inflammation is found in a large proportion of patients with OAB and IC\/BPS. The chronic inflammation activates sensory afferents which resulting in central sensitization and bladder storage symptoms. Because BoNT-A can inhibit the sensory peptides released from the vesicles in sensory nerve terminals, the inflammation can be reduced and symptom subsided. Previous studies have demonstrated that the quality of life improved after BoNT-A injections, both in neurogenic and non-NDO. Although the use of BoNT-A in treatment of IC\/BPS has not been approved by FDA, intravesical BoNT-A injection has been included in the AUA guideline as the fourth line therapy. Generally, intravesical injections of BoNT-A are well tolerated, though transient hematuria and urinary tract infection can occur after the procedure. In order to prevent these adverse events, experimental trials have been conducted to test if BoNT-A can be delivered into the bladder wall without intravesical injection under anesthesia such as using liposomes encapsulated BoNT-A or application of low energy shock wave on the bladder to facilitate BoNT-A penetrating across the urothelium and treat OAB or IC\/BPS. This article reviews current clinical and basic researches of BoNT-A on OAB and IC\/BPS.<\/jats:p>","DOI":"10.4103\/tcmj.tcmj_313_21","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T05:31:06Z","timestamp":1646976666000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis"],"prefix":"10.4103","volume":"35","author":[{"given":"Yuan-Hong","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Fong","family":"Jhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hann-Chorng","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03008880410015165","article-title":"Role of the urothelium in bladder function","volume":"215","author":"Birder","year":"2004","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.neuint.2004.06.001","article-title":"Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury","volume":"45","author":"Khera","year":"2004","journal-title":"Neurochem Int"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.eururo.2008.02.037","article-title":"Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity","volume":"53","author":"Apostolidis","year":"2008","journal-title":"Eur Urol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"E136","DOI":"10.1111\/j.1464-410X.2010.09911.x","article-title":"Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis\/painful bladder syndrome","volume":"108","author":"Shie","year":"2011","journal-title":"BJU Int"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"13.e7","DOI":"10.1016\/j.urology.2011.09.049","article-title":"Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis\/painful bladder syndrome","volume":"79","author":"Shie","year":"2012","journal-title":"Urology"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1464-410X.2012.11466.x","article-title":"Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis\/bladder pain syndrome","volume":"111","author":"Shie","year":"2013","journal-title":"BJU Int"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrurol.2015.193","article-title":"Current and potential urological applications of botulinum toxin A","volume":"12","author":"Jiang","year":"2015","journal-title":"Nat Rev Urol"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/nau.22445","article-title":"Targets for botulinum toxin in the lower urinary tract","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.neuint.2007.11.006","article-title":"Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury","volume":"52","author":"Smith","year":"2008","journal-title":"Neurochem Int"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.urology.2007.04.038","article-title":"Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis","volume":"70","author":"Liu","year":"2007","journal-title":"Urology"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.eururo.2008.04.037","article-title":"Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection","volume":"56","author":"Liu","year":"2009","journal-title":"Eur Urol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.juro.2008.01.146","article-title":"Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder","volume":"179","author":"Liu","year":"2008","journal-title":"J Urol"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2008.05.007","article-title":"Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats","volume":"56","author":"Chuang","year":"2009","journal-title":"Eur Urol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/nau.21132","article-title":"Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/nau.21246","article-title":"Mechanisms of action of botulinum neurotoxins, \u03b23-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011","volume":"31","author":"Kanai","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.urology.2012.12.021","article-title":"Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: A single-blind study","volume":"81","author":"Schulte-Baukloh","year":"2013","journal-title":"Urology"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urology"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/j.1742-1241.2008.01870.x","article-title":"Overactive bladder and continence guidelines: Implementation, inaction or frustration?","volume":"62","author":"Wagg","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/JU.0000000000000309","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019","volume":"202","author":"Lightner","year":"2019","journal-title":"J Urol"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4103\/tcmj.tcmj_167_20","article-title":"How to choose appropriate medication for overactive bladder \u2013 Findings from the largest integrated clinical trial database analysis of mirabegron studies","volume":"34","author":"Kuo","year":"2022","journal-title":"Tzu Chi Med J"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/UROS.UROS_46_21","article-title":"Videourodynamic precision diagnosis and treatment of female lower urinary tract symptoms","volume":"32","author":"Kuo","year":"2021","journal-title":"Urol Sci"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eururo.2005.12.012","article-title":"Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes","volume":"49","author":"Kalsi","year":"2006","journal-title":"Eur Urol"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2004.11.009","article-title":"Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence","volume":"47","author":"Grosse","year":"2005","journal-title":"Eur Urol"},{"key":"R25-20240828","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/jpet.110.169342","article-title":"Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers","volume":"334","author":"Lawrence","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/nau.21054","article-title":"Bladder base\/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics","volume":"30","author":"Kuo","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.juro.2007.05.136","article-title":"Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity","volume":"178","author":"Kuo","year":"2007","journal-title":"J Urol"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: A double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.juro.2016.10.109","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo controlled trial","volume":"197","author":"Nitti","year":"2017","journal-title":"J Urol"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.juro.2017.01.069","article-title":"The efficacy and safety of onabotulinumtoxinA or solifenacin compared with placebo in solifenacin na\u00efve patients with refractory overactive bladder: Results from a multicenter, randomized, double-blind phase 3b trial","volume":"198","author":"Herschorn","year":"2017","journal-title":"J Urol"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: Final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"key":"R33-20240828","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/iju.12912","article-title":"Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials","volume":"22","author":"Everaert","year":"2015","journal-title":"Int J Urol"},{"key":"R34-20240828","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/toxins8030082","article-title":"Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility","volume":"8","author":"Wang","year":"2016","journal-title":"Toxins (Basel)"},{"key":"R35-20240828","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: Medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"},{"key":"R36-20240828","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"R37-20240828","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"189","author":"Liao","year":"2013","journal-title":"J Urol"},{"key":"R38-20240828","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.juro.2015.01.086","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome: AUA guideline amendment","volume":"193","author":"Hanno","year":"2015","journal-title":"J Urol"},{"key":"R39-20240828","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1464-410X.2009.08495.x","article-title":"Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis\/painful bladder syndrome","volume":"104","author":"Kuo","year":"2009","journal-title":"BJU Int"},{"key":"R40-20240828","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2010.02.031","article-title":"Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome\/interstitial cystitis","volume":"58","author":"Pinto","year":"2010","journal-title":"Eur Urol"},{"key":"R41-20240828","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.36076\/ppj.2013\/16\/E15","article-title":"Repeated onabotulinumtoxin-A injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo","year":"2013","journal-title":"Pain Physician"},{"key":"R42-20240828","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1464-410x.2001.02190.x","article-title":"Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder","volume":"87","author":"Yiangou","year":"2001","journal-title":"BJU Int"},{"key":"R43-20240828","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2012.09.027","article-title":"Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome\/interstitial cystitis","volume":"189","author":"Pinto","year":"2013","journal-title":"J Urol"},{"key":"R44-20240828","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/01.ju.0000143189.19835.f3","article-title":"Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation","volume":"173","author":"Vemulakonda","year":"2005","journal-title":"J Urol"},{"key":"R45-20240828","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/iju.14585","article-title":"Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis\/bladder pain syndrome patients with Hunner's lesion and grade 3 glomerulation might be different from the other type patients","volume":"28","author":"Jhang","year":"2021","journal-title":"Int J Urol"},{"key":"R46-20240828","doi-asserted-by":"crossref","first-page":"e0198816","DOI":"10.1371\/journal.pone.0198816","article-title":"Electron microscopic characteristics of interstitial cystitis\/bladder pain syndrome and their association with clinical condition","volume":"13","author":"Jhang","year":"2018","journal-title":"PLoS One"},{"key":"R47-20240828","first-page":"608","article-title":"A possible explanation for the exceptional efficacy of botulinum toxin treatment for detrusor overactivity","volume":"23","author":"Apostolidis","year":"2004","journal-title":"Neurourol Urodyn"},{"key":"R48-20240828","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.ju.0000137844.77524.97","article-title":"Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats","volume":"172","author":"Chuang","year":"2004","journal-title":"J Urol"},{"key":"R49-20240828","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/ijcp.12113","article-title":"Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis\/bladder pain syndrome","volume":"67","author":"Kuo","year":"2013","journal-title":"Int J Clin Pract"},{"key":"R50-20240828","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/nau.22760","article-title":"Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis\/bladder pain syndrome refractory to conventional treatment \u2013A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"35","author":"Kuo","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"R51-20240828","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.juro.2017.10.018","article-title":"Intratrigonal onabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome\/interstitial cystitis: A pilot, single center, randomized, double-blind, placebo controlled trial","volume":"199","author":"Pinto","year":"2018","journal-title":"J Urol"},{"key":"R52-20240828","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/toxins11090510","article-title":"Botulinum neurotoxin A intravesical injections in interstitial cystitis\/bladder painful syndrome: A systematic review with meta-analysis","volume":"11","author":"Giannantoni","year":"2019","journal-title":"Toxins (Basel)"},{"key":"R53-20240828","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J Urol"},{"key":"R54-20240828","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.urology.2008.04.026","article-title":"Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection","volume":"72","author":"Kuo","year":"2008","journal-title":"Urology"},{"key":"R55-20240828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.sc.3102070","article-title":"Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: A systematic review of effectiveness and adverse effects","volume":"45","author":"MacDonald","year":"2007","journal-title":"Spinal Cord"},{"key":"R56-20240828","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2174\/1389450121666200621194732","article-title":"Intravesical botox for overactive bladder: How to minimize complications and manage failures","volume":"21","author":"Apostolidis","year":"2020","journal-title":"Curr Drug Targets"},{"key":"R57-20240828","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.juro.2009.03.083","article-title":"Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes","volume":"182","author":"Chuang","year":"2009","journal-title":"J Urol"},{"key":"R58-20240828","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.eururo.2014.01.036","article-title":"Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: A single-center study","volume":"65","author":"Kuo","year":"2014","journal-title":"Eur Urol"},{"key":"R59-20240828","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2014.07.008","article-title":"Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: A prospective, multicenter, double-blind, randomized trial","volume":"192","author":"Chuang","year":"2014","journal-title":"J Urol"},{"key":"R60-20240828","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/toxins13050359","article-title":"Novel applications of non-invasive intravesical botulinum toxin a delivery in the treatment of functional bladder disorders","volume":"13","author":"Jhang","year":"2021","journal-title":"Toxins (Basel)"}],"container-title":["Tzu Chi Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_313_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:51Z","timestamp":1787166471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tcmj.tcmj_313_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/tcmj.tcmj_313_21","relation":{},"ISSN":["1016-3190","2223-8956"],"issn-type":[{"value":"1016-3190","type":"print"},{"value":"2223-8956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"2021-11-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}